Abstract: OBJECTIVE To observe the short-term and long-term clinical effect of Shenning Ⅱ decoction in the treatment of chronic kidney disease(CKD) of phase 2-5 by retrospective analysis method. METHODS A total of 198 patients were included in the study, 124 cases in the treatment group(received Shenning Ⅱ decoction and basic treatment) and 74 cases in the control group(received basic treatment). The change of renal function, serum uric acid and liver function in 2 groups were observed at 2 weeks after treatment. Eighty-two patients(59 cases in treatment group, 23 cases in control group) were continued treatment and followed up for 3 months, and the trend of renal function was observed by linear regression of slope b of reciprocal serum creatinine(1/Scr) with time(month), and the number of patients with end-stage renal failure(ESRD) in 3 years was predicted theoretically. RESULTS The total effective rate of the treatment group was higher than the control group(66.94% vs 51.35%, P<0.05), the total effective rate of patients of CKD5 and patients of non-diabetic kidney disease(NDKD) in the treatment group was higher than that of the control group(67.44% vs 39.13%, 71.43% vs 53.49%, P<0.05). About the long-term curative effect, the treatment group b value was higher than that of the control group, the number of positive b value of the treatment group was higher than the control group, the number of cases with ESRD predicted in the 3 year was less than that in the control group. The long-term curative effect is better in the treatment group(P<0.05). CONCLUSION On the basis of routine treatment, the Shenning Ⅱ decoction can improve renal function of CKD of phase 2-5 with NDKD patients and delay the progression of renal failure patients.